Cardiovascular disease (CVD) Segment has the Largest Share of Type in the South and Central America Cardiometabolic Diseases Market during 2021–2028
According to our latest study on “South and Central America Cardiometabolic Diseases Market Forecast to 2028 – COVID-19 Impact and Analysis – by Type, Treatment, Dosage, Route of Administration, End User, and Distribution Channel,” the market is projected to reach US$ 10,295.5 million by 2028 from US$ 8,472.6 million in 2021; it is expected to grow at a CAGR of 2.8% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increasing prevalence of cardiometabolic diseases, and innovation in cardiometabolic diseases therapeutics. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) is hampering the growth of the market to a certain extent.
Brazil, Argentina, Uruguay, Chile, Peru, Colombia is concerned by the second wave of corona infection. Amongst which Brazil has registered the majority of the deaths. It is anticipated that the region will likely force a second lockdown, which will ultimately hamper the healthcare industry in the area. There have been intensive attempts to explore drug therapy to prevent and treat SARS-CoV-2 infection during this COVID-19 pandemic. Thus, the ongoing clinical studies regarding cardiometabolic diseases market for COVID in the region is likely to favor the growth of the market.
Based on type, the South and Central America cardiometabolic diseases market is bifurcated into cardiovascular disease, type 2 diabetes, hypertension, and obesity. In 2021, the cardiovascular disease segment is likely to account for the highest share of the market. Growth of this segment is majorly attributed to the increasing hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents. Furthermore, the increasing R&D activities in the pharmaceutical’s companies, ageing population is likely to create opportunity in the forecast year.
Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Kowa Company, Ltd., Novo Nordisk A/S, and AstraZeneca are among the leading companies in the South and Central America cardiometabolic diseases market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.
The market for cardiometabolic diseases market is bifurcated into type, treatment, dosage, route of administration, end user, and distribution channel. Based on type, the South and Central America cardiometabolic diseases market is segmented into cardiovascular disease (CVD), type 2 diabetes, hypertension, and obesity. Based on treatment, the cardiometabolic diseases market is segmented into ACE inhibitors, diuretics, glucophage, and others. Based on dosage, the cardiometabolic diseases market is segmented into tablet, and injection. Based on route of administration, the cardiometabolic diseases market is segmented into oral, and intravenous. Based on end user, the cardiometabolic diseases market is segmented into hospital, clinic, and homecare settings. Based on distribution channel, the cardiometabolic diseases market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Geographically, the cardiometabolic diseases market is segmented into South and Central America (Brazil, Argentina, Rest of South and Central America).
The report segments South and Central America cardiometabolic diseases market as follows:
The South and Central America cardiometabolic diseases market is segmented on the basis on ingredient type and sources. Based on ingredient type, the South and Central America cardiometabolic diseases market is segmented into Probiotics and prebiotics, omega-3 fatty acids, vitamins, carotenoids and antioxidants, plant extracts, minerals, amino acids, proteins and peptides, and others. Based on sources, the market is segmented into plant animal, and microbial.
By Country
- UK
- Germany
- France
- Italy
- Spain
- Rest of South and Central America
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com